Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426

PURPOSE: To evaluate the efficacy and toxicity of pemetrexed combined with bevacizumab as second-line therapy for patients with advanced non–small-cell lung cancer (NSCLC) and to correlate allelic variants in pemetrexed-metabolizing genes with clinical outcome. PATIENTS AND METHODS: Patients with pr...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Adjei, Alex A., Mandrekar, Sumithra J., Dy, Grace K., Molina, Julian R., Adjei, Araba A., Gandara, David R., Ziegler, Katie L. Allen, Stella, Philip J., Rowland, Kendrith M., Schild, Steven E., Zinner, Ralph G.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2010
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2815996/
https://ncbi.nlm.nih.gov/pubmed/19841321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.23.6406
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky